Thus, rational design of inhibitors that modulate APTX‐DNA‐end and DNA‐nick deadenylation activities stemming from this work could be useful for treatment of cancers, or as a co‐therapy with existing chemotherapeutics that induce “dirty” complex structured DNA breaks. This evidence concerns the gene APTX and cancer.